keyword
https://read.qxmd.com/read/35339669/are-they-side-effects-extraintestinal-symptoms-reported-during-clinical-trials-of-irritable-bowel-syndrome-may-be-more-severe-at-baseline
#21
JOURNAL ARTICLE
Sarah Ballou, Rafla Hassan, Judy Nee, Johanna Iturrino, Vikram Rangan, Vivian Cheng, Lisa Conboy, Irving Kirsch, Anthony Lembo, Ted J Kaptchuk, John Kelley
BACKGROUND & AIMS: Many of the reported adverse events in clinical trials of irritable bowel syndrome are extraintestinal symptoms, which typically are assessed by open-ended questions during the trial and not at baseline. This may lead to misattribution of some pre-existing symptoms as side effects to the treatment. METHODS: The current study analyzed data from a 6-week clinical trial of irritable bowel syndrome. Participants were randomized to receive double-blind peppermint oil, double-blind placebo, or treatment as usual...
March 23, 2022: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/35120572/patients-experiences-treated-with-open-label-placebo-versus-double-blind-placebo-a-mixed-methods-qualitative-study
#22
RANDOMIZED CONTROLLED TRIAL
Julia W Haas, Giulio Ongaro, Eric Jacobson, Lisa A Conboy, Judy Nee, Johanna Iturrino, Vikram Rangan, Anthony Lembo, Ted J Kaptchuk, Sarah Ballou
BACKGROUND: There is increasing evidence suggesting that open-label placebo (OLP) is an effective treatment for several medical conditions defined by self-report. However, little is known about patients' experiences with OLP, and no studies have directly compared patients' experiences in double-blind placebo (DBP) conditions. METHODS: This study was nested in a large randomized-controlled trial comparing the effects of OLP and DBP treatments in individuals with irritable bowel syndrome (IBS)...
February 4, 2022: BMC Psychology
https://read.qxmd.com/read/35099543/effect-of-open-label-placebo-on-children-and-adolescents-with-functional-abdominal-pain-or-irritable-bowel-syndrome-a-randomized-clinical-trial
#23
RANDOMIZED CONTROLLED TRIAL
Samuel Nurko, Miguel Saps, Joe Kossowsky, Sean Raymond Zion, Carlo Di Lorenzo, Karla Vaz, Kelsey Hawthorne, Rina Wu, Steven Ciciora, John Michael Rosen, Ted J Kaptchuk, John M Kelley
IMPORTANCE: Although it is widely believed that concealment or deception is required to elicit a placebo response, recent studies with adults suggest that open-label placebo (OLP) (ie, honestly prescribed placebos) can yield significant benefits. No studies of OLP have been performed with children. OBJECTIVE: To evaluate the efficacy of OLP for the treatment of children and adolescents with functional abdominal pain or irritable bowel syndrome. DESIGN, SETTING, AND PARTICIPANTS: This multicenter crossover randomized clinical trial was conducted from July 1, 2015, to June 15, 2018, at 3 US centers among children and adolescents aged 8 to 18 years with functional abdominal pain or irritable bowel syndrome defined per Rome III criteria...
April 1, 2022: JAMA Pediatrics
https://read.qxmd.com/read/35091536/patient-clinician-brain-concordance-underlies-causal-dynamics-in-nonverbal-communication-and-negative-affective-expressivity
#24
JOURNAL ARTICLE
Dan-Mikael Ellingsen, Andrea Duggento, Kylie Isenburg, Changjin Jung, Jeungchan Lee, Jessica Gerber, Ishtiaq Mawla, Roberta Sclocco, Robert R Edwards, John M Kelley, Irving Kirsch, Ted J Kaptchuk, Nicola Toschi, Vitaly Napadow
Patient-clinician concordance in behavior and brain activity has been proposed as a potential key mediator of mutual empathy and clinical rapport in the therapeutic encounter. However, the specific elements of patient-clinician communication that may support brain-to-brain concordance and therapeutic alliance are unknown. Here, we investigated how pain-related, directional facial communication between patients and clinicians is associated with brain-to-brain concordance. Patient-clinician dyads interacted in a pain-treatment context, during synchronous assessment of brain activity (fMRI hyperscanning) and online video transfer, enabling face-to-face social interaction...
January 28, 2022: Translational Psychiatry
https://read.qxmd.com/read/35040967/frequency-of-adverse-events-in-the-placebo-arms-of-covid-19-vaccine-trials-a-systematic-review-and-meta-analysis
#25
JOURNAL ARTICLE
Julia W Haas, Friederike L Bender, Sarah Ballou, John M Kelley, Marcel Wilhelm, Franklin G Miller, Winfried Rief, Ted J Kaptchuk
Importance: Adverse events (AEs) after placebo treatment are common in randomized clinical drug trials. Systematic evidence regarding these nocebo responses in vaccine trials is important for COVID-19 vaccination worldwide especially because concern about AEs is reported to be a reason for vaccination hesitancy. Objective: To compare the frequencies of AEs reported in the placebo groups of COVID-19 vaccine trials with those reported in the vaccine groups. Data Sources: For this systematic review and meta-analysis, the Medline (PubMed) and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched systematically using medical subheading terms and free-text keywords for trials of COVID-19 vaccines published up to July 14, 2021...
January 4, 2022: JAMA Network Open
https://read.qxmd.com/read/34903861/placebo-effects-and-neuromodulation-for-depression-a-meta-analysis-and-evaluation-of-shared-mechanisms
#26
JOURNAL ARTICLE
Matthew J Burke, Sara M Romanella, Lucia Mencarelli, Rachel Greben, Michael D Fox, Ted J Kaptchuk, Alvaro Pascual-Leone, Emiliano Santarnecchi
There is growing evidence that placebo effects can meaningfully modulate the brain. However, there has been little consideration of whether these changes may overlap with regions/circuits targeted by depression treatments and what the implications of this overlap would be on measuring efficacy in placebo-controlled clinical trials. In this systematic review and meta-analysis, we searched PubMed/Medline and Google Scholar for functional MRI and PET neuroimaging studies of placebo effects. Studies recruiting both healthy subjects and patient populations were included...
March 2022: Molecular Psychiatry
https://read.qxmd.com/read/34541967/psychological-interventions-for-the-treatment-of-chronic-pain-in-adults
#27
JOURNAL ARTICLE
Mary A Driscoll, Robert R Edwards, William C Becker, Ted J Kaptchuk, Robert D Kerns
The high prevalence and societal burden of chronic pain, its undertreatment, and disparities in its management have contributed to the acknowledgment of chronic pain as a serious public-health concern. The concurrent opioid epidemic, and increasing concern about overreliance on opioid therapy despite evidence of limited benefit and serious harms, has heightened attention to this problem. The biopsychosocial model has emerged as the primary conceptual framework for understanding the complex experience of chronic pain and for informing models of care...
September 2021: Psychological Science in the Public Interest: a Journal of the American Psychological Society
https://read.qxmd.com/read/34509775/durability-of-treatment-response-to-zolpidem-using-a-partial-reinforcement-regimen-does-this-strategy-require-priming
#28
RANDOMIZED CONTROLLED TRIAL
Michael L Perlis, Knashawn H Morales, Ivan Vargas, Alexandria Muench, Mark Seewald, Nalaka Gooneratne, Michael A Grandner, Michael E Thase, Ted J Kaptchuk, Robert Ader
BACKGROUND: Previous research has shown that after one month of full dose nightly treatment with zolpidem (priming), subjects with chronic insomnia (CI) switched to intermittent dosing with medication and placebos were able to maintain their treatment responses. This approach to maintenance therapy is referred to as partial reinforcement. The present study sought to assess whether priming is required for partial reinforcement or whether intermittent dosing with placebos (50% placebos and 50% active medication) can, by itself, be used for both acute and extended treatment...
November 2021: Sleep Medicine
https://read.qxmd.com/read/34319275/peppermint-oil-treatment-for-irritable-bowel-syndrome-a-randomized-placebo-controlled-trial
#29
RANDOMIZED CONTROLLED TRIAL
Judy Nee, Sarah Ballou, John M Kelley, Ted J Kaptchuk, William Hirsch, Jesse Katon, Vivian Cheng, Vikram Rangan, Anthony Lembo, Johanna Iturrino
INTRODUCTION: Peppermint oil is often used to treat irritable bowel syndrome (IBS); however, the overall quality of previous studies is low, and findings have been heterogeneous. This study aimed to compare the effects of peppermint oil vs placebo in relieving IBS symptoms. METHODS: In a 6-week, randomized, double-blind, placebo-controlled trial at a single academic center in the United States, individuals diagnosed with IBS (Rome IV criteria), with moderate to severe symptoms based on the IBS Severity Scoring System (IBS-SSS score ≥175), were randomized to enteric-coated peppermint oil 180 mg 3 times daily vs placebo in a 1:2 ratio...
November 1, 2021: American Journal of Gastroenterology
https://read.qxmd.com/read/34267689/an-exploratory-analysis-of-the-association-between-catechol-o-methyltransferase-and-response-to-a-randomized-open-label-placebo-treatment-for-cancer-related-fatigue
#30
JOURNAL ARTICLE
Teri W Hoenemeyer, Navneet Kaur Baidwan, Kathryn Hall, Ted J Kaptchuk, Kevin R Fontaine, Tapan S Mehta
Previous studies have identified catechol-O-methyltransferase (COMT), as a key enzyme influencing sympathetic function. Although the COMT SNP rs4680 and rs4818, are well-studied, little is known about their influence on cancer-related fatigue (CrF) and placebo response. In this study, we examined whether genetic variation in COMT , at the functional SNP rs4680 and linked rs4818, influenced open-label placebo (OLP) responses found in cancer survivors reporting moderate to severe CrF. We randomized cancer survivors ( N = 74) reporting moderate-to-severe CrF to receive OLP or to treatment-as-usual (TAU) and assessed if rs4680 and rs4818 were associated with changes in fatigue severity and fatigue-distressed quality of life...
2021: Frontiers in Psychiatry
https://read.qxmd.com/read/34165044/surgeons-behaviors-and-beliefs-regarding-placebo-effects-in-surgery
#31
JOURNAL ARTICLE
Annelie Rosén, Lisbeth Sachs, Amanda Ekdahl, Andreas Westberg, Paul Gerdhem, Ted J Kaptchuk, Karin Jensen
Background and purpose - Emerging evidence from sham-controlled trials suggest that surgical treatment entails substantial non-specific treatment effects in addition to specific surgical effects. Yet, information on surgeons' actual behaviors and beliefs regarding non-specific treatment and placebo effects is scarce. We determined surgeons' clinical behaviors and attitudes regarding placebo effects.Methods - A national online survey was developed in collaboration with surgeons and administered via an electronic link...
October 2021: Acta Orthopaedica
https://read.qxmd.com/read/34091518/improving-medication-tolerance-a-pilot-study-in-disorders-of-gut-brain-interaction-treated-with-tricyclic-antidepressants
#32
RANDOMIZED CONTROLLED TRIAL
Sarah Ballou, Johanna Iturrino, Vikram Rangan, Vivian Cheng, John M Kelley, Anthony Lembo, Ted J Kaptchuk, Judy Nee
OBJECTIVES: Tricyclic antidepressants (TCAs) are commonly used to treat disorders of gut-brain interaction (DGBI). However, these medications are often associated with side effects that lead to early treatment discontinuation. Research in other chronic medical conditions suggests that many TCA side effects may be caused by nocebo (negative placebo) effects. The current study tests a brief, verbal intervention aimed at improving tolerance of TCAs in DGBI by providing education about nocebo effects...
May 2022: Journal of Clinical Gastroenterology
https://read.qxmd.com/read/33979308/a-conversation-with-%C3%A2-ted-j-kaptchuk-expert-in-placebo-effects
#33
Seth S Leopold
No abstract text is available yet for this article.
August 1, 2021: Clinical Orthopaedics and related Research
https://read.qxmd.com/read/33941677/manipulating-placebo-analgesia-and-nocebo-hyperalgesia-by-changing-brain-excitability
#34
RANDOMIZED CONTROLLED TRIAL
Yiheng Tu, Georgia Wilson, Joan Camprodon, Darin D Dougherty, Mark Vangel, Fabrizio Benedetti, Ted J Kaptchuk, Randy L Gollub, Jian Kong
Harnessing placebo and nocebo effects has significant implications for research and medical practice. Placebo analgesia and nocebo hyperalgesia, the most well-studied placebo and nocebo effects, are thought to initiate from the dorsal lateral prefrontal cortex (DLPFC) and then trigger the brain's descending pain modulatory system and other pain regulation pathways. Combining repeated transcranial direct current stimulation (tDCS), an expectancy manipulation model, and functional MRI, we investigated the modulatory effects of anodal and cathodal tDCS at the right DLPFC on placebo analgesia and nocebo hyperalgesia using a randomized, double-blind and sham-controlled design...
May 11, 2021: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/33759705/ethical-and-legal-considerations-of-alternative-neurotherapies
#35
REVIEW
Ashwini Nagappan, Louiza Kalokairinou, Anna Wexler
Neurotherapies for diagnostics and treatment-such as electroencephalography (EEG) neurofeedback, single-photon emission computerized tomography (SPECT) imaging for neuropsychiatric evaluation, and off-label/experimental uses of brain stimulation-are continuously being offered to the public outside mainstream healthcare settings. Because these neurotherapies share many key features of complementary and alternative medicine (CAM) techniques-and meet the definition of CAM as set out in Kaptchuk and Eisenberg-here we refer to them as "alternative neurotherapies...
October 2021: AJOB Neuroscience
https://read.qxmd.com/read/33605656/open-label-placebo-vs-double-blind-placebo-for-irritable-bowel-syndrome-a-randomized-clinical-trial
#36
JOURNAL ARTICLE
Anthony Lembo, John M Kelley, Judy Nee, Sarah Ballou, Johanna Iturrino, Vivian Cheng, Vikram Rangan, Jesse Katon, William Hirsch, Irving Kirsch, Kathryn Hall, Roger B Davis, Ted J Kaptchuk
It is commonly believed that blinding to treatment assignment is necessary for placebos to have an effect. However, placebos administered without concealment (i.e., open-label placebos [OLP]) have recently been shown to be effective in some conditions. This study had two objectives: first, to determine whether OLP treatment is superior to no-pill control (NPC) in irritable bowel syndrome (IBS); and second, to compare the efficacy of OLP against double-blind placebo (DBP). In a six-week, three-arm, randomized clinical trial, participants were randomized in equal proportions to three arms: OLP, DBP or NPC...
February 12, 2021: Pain
https://read.qxmd.com/read/33449503/conditioned-open-label-placebo-for-opioid-reduction-following-spine-surgery-a-randomized-controlled-trial
#37
JOURNAL ARTICLE
K Mikayla Flowers, Megan E Patton, Valerie J Hruschak, Kara G Fields, Emily Schwartz, Jose Zeballos, James D Kang, Rob R Edwards, Ted J Kaptchuk, Kristin L Schreiber
Placebo effects have traditionally involved concealment or deception. However, recent evidence suggests that placebo effects can also be elicited when prescribed transparently as "open-label placebos" (OLP), and that the pairing of an unconditioned stimulus (e.g., opioid analgesic) with a conditioned stimulus (e.g., placebo pill) can lead to the conditioned stimulus alone reducing pain. In this randomized control trial, we investigated whether combining conditioning with an open-label placebo (COLP) in the immediate postoperative period could reduce daily opioid use and postsurgical pain among patients recovering from spine surgery...
January 11, 2021: Pain
https://read.qxmd.com/read/33362886/placebo-effects-in-acupuncture
#38
REVIEW
Ted J Kaptchuk
This article is a summary of a talk presented in February 2019 at a conference on acupuncture sponsored by the National Institutes of Cancer (NCI) and the National Center for Complementary and Integrative Health (NCCIH) at the National of Institutes of Health (NIH). The article touches on the history of placebos in biomedicine and its absence in traditional East Asian Medicine. It then examines some of the predicaments of evaluating acupuncture's efficacy in relationship to placebo controls. Although acupuncture in randomized controlled trials (RCTs) generally demonstrate equivalence or even superiority to medical interventions or other nonpharmacologic therapies, acupuncture's ability to show superiority to placebo controls has been inconclusive, contradictory and, at best, modest...
December 1, 2020: Medical Acupuncture
https://read.qxmd.com/read/33312762/a-4-month-whole-systems-ayurvedic-medicine-nutrition-and-lifestyle-intervention-is-feasible-and-acceptable-for-breast-cancer-survivors-results-of-a-single-arm-pilot-clinical-trial
#39
JOURNAL ARTICLE
Anand Dhruva, Cairn Wu, Christine Miaskowski, Wendy Hartogensis, Hope S Rugo, Shelley R Adler, Ted J Kaptchuk, Rucha Kelkar, Sangeeta Agarawal, Amisha Vadodaria, Ellen Garris, Frederick M Hecht
PURPOSE: Ongoing symptoms and impairments in quality of life (QOL) among breast cancer survivors remain a significant problem. We tested the feasibility and acceptability of a manualized Ayurvedic nutrition and lifestyle intervention for breast cancer survivors. METHODS: Eligible participants had Stage I-III breast cancer, underwent treatment within the past year that included chemotherapy, and were without active disease. The 4-month individualized Ayurvedic intervention included counseling on nutrition, lifestyle, yoga, and marma (like acupressure) during 8 one-on-one visits with an Ayurvedic practitioner...
2020: Global Advances in Health and Medicine: Improving Healthcare Outcomes Worldwide
https://read.qxmd.com/read/33259459/open-label-placebo-for-chronic-low-back-pain-a-5-year-follow-up
#40
RANDOMIZED CONTROLLED TRIAL
Claudia Carvalho, Maria Pais, Lidia Cunha, Paula Rebouta, Ted J Kaptchuk, Irving Kirsch
Long-term follow-up of patients treated with open-label placebo (OLP) are nonexistent. In this article, we report a 5-year follow-up of a 3-week OLP randomized controlled trial (RCT) in patients with chronic low back pain. We recontacted the participants of original RCT and reassessed their pain, disability, and use of pain medication. We obtained follow-up data from 55 participants (82% of those who took OLP during the parent RCT), with a mean elapsed time between the end of the 3 weeks placebo trial and the follow-up interview of 55 months (SD = 7...
May 1, 2021: Pain
keyword
keyword
108955
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.